5th Annual International Conference on HDL Cholesterol: metabolic pathways and drug developments.
Cardiovascular diseases (CVD) are the number one killer in the USA and are likely to be a significant cause of mortality in developing countries in the near future. High levels of high-density lipoprotein (HDL) are known to be inversely related to CVD incidence. However, whether or not HDL plays a direct preventative role or is simply a coincident marker for other protective processes has been controversial. Fortunately, recent discoveries have dramatically increased understanding of HDL function and recent clinical studies suggest that raising HDL levels may indeed be an effective strategy for preventing CVD. This meeting was organised to highlight state-of-the art studies focusing on the mechanisms of HDL function. Important work concerning small-molecule and immunological approaches for raising HDL were presented, including the targeting of regulatory nuclear receptors, plasma enzymes/transfer proteins that remodel HDL, and cell surface proteins that influence HDL formation and function. A detailed understanding of the molecular basis for the protective effect of HDL will hopefully lead to the development of new therapeutics that exploit this pathway.
Department of Pathology, University of Cincinnati Genome Research Institute, 2120 East Galbraith Road, Building A ML 0507, Cincinnati, OH 45237, USA. Sean.Davidson@UC.edu
W Sean
WS
Davidson
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D006801:Humans; D038622:Internationality; D008404:Massachusetts; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends*
D008076:Cholesterol, HDL